Get the Stockscreener App
1.51
5.63%
-0.09
Allogene Therapeutics Inc stock is traded at $1.51, with a volume of 1.45M.
It is down -5.63% in the last 24 hours and down -35.74% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.60
Open:
$1.6
24h Volume:
1.45M
Relative Volume:
0.54
Market Cap:
$335.48M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.7123
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-16.11%
1M Performance:
-35.74%
6M Performance:
-38.87%
1Y Performance:
-63.61%
1-Day Range:
$1.51
$1.61
1-Week Range:
$1.51
$1.78
52-Week Range:
$1.51
$5.775
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.51 | 335.48M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.88 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.49 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.66 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,950.84 in Stock - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Follicular Lymphoma Pipeline 2024: Comprehensive Clinical - openPR
Allogene Therapeutics Announces Participation in February Investor Conferences - GlobeNewswire
Allogene Therapeutics Joins Elite Biotech Lineup at Major Oppenheimer Conference - StockTitan
Allogene stock hits 52-week low at $1.76 amid market challenges - Investing.com
Allogene Therapeutics executive to depart, consulting agreement planned - MSN
Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News
Allogene Therapeutics, Inc. Announces Departure of Timothy MooreOn January 23, 2025, Allogene Therapeutics, Inc. (NASDAQ: ALLO) revealed in an 8-K filing that Timothy Moore, the Company’s incumbent executive, would be concluding his tenure with the - Defense World
Allogene Therapeutics executive to depart, consulting agreement planned By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer - BioSpace
Allogene Therapeutics Announces Executive Departure and Transition - TipRanks
Allogene’s ALLO-329 gains IND clearance for autoimmune diseases - BioWorld Online
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
Allogene gains FDA IND clearance for CAR T candidate for lupus - MSN
Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive™
Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate - Marketscreener.com
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - The Manila Times
Game-Changing Autoimmune Treatment: Allogene's Novel CAR T Targets Both B-cells and T-cells - StockTitan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells $48,414.22 in Stock - MarketBeat
Advancing LBCL Treatment Through MRD Monitoring and Allogeneic CAR T-Cell Therapy - Pharmacy Times
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
What is Zacks Research's Forecast for ALLO Q2 Earnings? - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.73 Consensus Price Target from Brokerages - MarketBeat
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC - Defense World
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Allogene Therapeutics Inc Stock (ALLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER |
Feb 03 '25 |
Sale |
1.73 |
4,361 |
7,545 |
1,301,540 |
| MOORE TIMOTHY L. | Chief Technical Officer |
Feb 03 '25 |
Sale |
1.71 |
14,746 |
25,216 |
250,713 |
| Chang David D | President and CEO |
Feb 03 '25 |
Sale |
1.68 |
46,003 |
77,285 |
5,317,237 |
| Roberts Zachary | EVP of R&D |
Feb 03 '25 |
Sale |
1.70 |
18,832 |
32,014 |
643,135 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):